Endothelial Function and Progenitor Cells in Acute Ischemic Stroke "EPCAS"


Phase N/A Results N/A

Trial Description

The purpose of this study is to determine whether levels of circulating endothelial progenitor cells (cEPC) are increased in the acute phase of ischemic stroke.

Detailed Description

Endothelial dysfunction is a key component of atherosclerosis which contributes to the development of cardio- and cerebrovascular diseases. However, endothelial dysfunction (ED) is not established as a risk factor for ischemic stroke.
As a novelty the proposed trial investigates the following variety of indirect markers of endothelial function in acute ischemic stroke:
circulating endothelial progenitor cells (EPC), endothelial microparticles (EMP), ENDOPAT (RH- PAT ratio) in two regards:
1. time after ischemic events (< 48h, Days 4-5, day 7 or at discharge)
2. etiological stroke subtypes
It is not known whether these parameters are changed after acute cerebral ischemia and could possibly serve as specific target for treatment.


Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Non-Probability Sample

Trial Population

Patients with first-ever ischemic stroke transferred to our stroke unit


Type Measure Time Frame Safety Issue
Primary Levels of cEPC <48h, day 4-5, discharge or day 7 No
Secondary Levels of EMP <48h, day 4-5, day 7 or discharge No
Secondary ENDOPAT <48h, day 4-5,day 7 No

Biospecimen Retention:Samples Without DNA - whole blood, serum, PBMC, plasma